Navigation Links
New 'Achilles' heel' in breast cancer: Tumor cell mitochondria
Date:12/1/2011

PHILADELPHIA -- Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.

Reporting in the online Dec.1 issue of Cell Cycle, Michael P. Lisanti, M.D., Ph.D., Professor and Chair of Stem Cell Biology & Regenerative Medicine at Thomas Jefferson University, and colleagues provide the first in vivo evidence that breast cancer cells perform enhanced mitochondrial oxidative phosphorylation (OXPHOS) to produce high amounts of energy.

"We and others have now shown that cancer is a 'parasitic disease' that steals energy from the host -- your body," Dr. Lisanti said, "but this is the first time we've shown in human breast tissue that cancer cell mitochondria are calling the shots and could ultimately be manipulated in our favor."

Mitochondria are the energy-producing power-plants in normal cells. However, cancer cells have amplified this energy-producing mechanism, with at least five times as much energy-producing capacity, compared with normal cells. Simply put, mitochondria are the powerhouse of cancer cells and they fuel tumor growth and metastasis.

The research presented in the study further supports the idea that blocking this activity with a mitochondrial inhibitor -- for instance, an off-patent generic drug used to treat diabetes known as Metformin -- can reverse tumor growth and chemotherapy resistance. This new concept could radically change how we treat cancer patients, and stimulate new metabolic strategies for cancer prevention and therapy.

Investigating the Powerhouse

Whether cancer cells have functional mitochondria has been a hotly debated topic for the past 85 years. It was argued that cancer cells don't use mitochondria, but instead use glycolysis exclusively; this is known as the Warburg Effect. But researchers at the Jefferson's KCC have shown that this inefficient method of producing energy actually takes place in the surrounding host stromal cells, rather then in epithelial cancer cells. This process then provides abundant mitochondrial fuel for cancer cells. They've coined this the "Reverse Warburg Effect," the opposite or reverse of the existing paradigm.

To study mitochondria's role directly, the researchers, including co-author and collaborator Federica Sotgia, Assistant Professor in the Department of Cancer Biology, looked at mitochondrial function using COX activity staining in human breast cancer samples. Previously, this simple stain was only applied to muscle tissue, a mitochondrial-rich tissue.

Researchers found that human breast cancer epithelial cells showed amplified levels of mitochondrial activity. In contrast, adjacent stromal tissues showed little or no mitochondrial oxidative capacity, consistent with the new paradigm. These findings were further validated using a computer-based informatics approach with gene profiles from over 2,000 human breast cancer samples.

It is now clear that cancer cell mitochondria play a key role in "parasitic" energy transfer between normal fibroblasts and cancer cells, fueling tumor growth and metastasis.

"We have presented new evidence that cancer cell mitochondria are at the heart of tumor cell growth and metastasis," Dr. Lisanti said. "Metabolically, the drug Metformin prevents cancer cells from using their mitochondria, induces glycolysis and lactate production, and shifts cancer cells toward the conventional 'Warburg Effect'. This effectively starves the cancer cells to death".

Personalized Treatment

Although COX mitochondrial activity staining had never been applied to cancer tissues, it could now be used routinely to distinguish cancer cells from normal cells, and to establish negative margins during cancer surgery. And this is a very cost-effective test, since it has been used routinely for muscle-tissue for over 50 years, but not for cancer diagnosis.

What's more, it appears that upregulation of mitochondrial activity is a common feature of human breast cancer cells, and is associated with both estrogen receptor positive (ER+) and negative (ER-) disease. Outcome analysis indicated that this mitochondrial gene signature is also associated with an increased risk of tumor cell metastasis, particularly in ER-negative (ER-) patients.

"Mitochondria are the 'Achilles' heel' of tumor cells," Dr. Lisanti said. "And we believe that targeting mitochondrial metabolism has broad implications for both cancer diagnostics and therapeutics, and could be exploited in the pursuit of personalized cancer medicine."


'/>"/>
Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related biology news :

1. Genome sequence could reveal Achilles heels of important wheat disease
2. Scientists uncover Achilles heel of chronic inflammatory pain
3. Scientists discover influenzas Achilles heel: Antioxidants
4. Aussie meat ants may be invasive cane toads Achilles heel
5. UC Davis researchers discover Achilles heel in pancreatic cancer
6. Researchers identify Achilles heel of common childhood tumor
7. Reinventing the wheel -- naturally
8. Human use heel first gait because it is efficient for walking
9. Short heels make elite sprinters super speedy
10. Medicine wheel model for nutrition shows promise for control of type 2 diabetes
11. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New 'Achilles' heel' in breast cancer: Tumor cell mitochondria
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... to a comprehensive library of reports on Valero Energy ... transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... biofuel production to go green. Ethanol today, even though touted ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017  Trovagene, ... announced that its Chief Executive Officer, Bill Welch ... on April 4, 2017 at 9:00 AM EDT at ... .  Bill Welch, and Chief Scientific Officer, ... meet with investors during the conference.   The ...
(Date:3/24/2017)... 24, 2017 MiMedx Group, Inc. (NASDAQ: MDXG), ... placental tissue allografts and patent-protected processes to develop and ... healthcare, announced today  that it will present at the ... , NY.  Parker H. "Pete" Petit, Chairman and CEO, ... Christopher M. Cashman , EVP and Chief Commercialization Officer, ...
(Date:3/24/2017)... BEIJING , March 24, 2017 Sinovac Biotech Ltd. ... products in China , today announced that its ... the expiration date of the plan from March 27, 2017 to ... proposal. About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is ...
Breaking Biology Technology: